Skip to main content
Top
Published in: Archives of Virology 1/2018

01-01-2018 | Original Article

Association of interferon lambda polymorphisms with elevated baseline viral loads in chronic hepatitis C virus genotype 6 infection

Authors: Linh Thuy Nguyen, Dzung Van Nguyen, Michael J. Carr, William W. Hall, Lan Anh Nguyen

Published in: Archives of Virology | Issue 1/2018

Login to get access

Abstract

Globally, hepatitis C virus (HCV) is one of the major causes of hepatocellular carcinoma and liver cirrhosis. For clinical decision making, genetic variation in the interferon-λ (IFNL) cluster has been utilised as a baseline predictor of natural and interferon-based treatment-induced viral clearance. In Vietnam, where HCV genotypes 1 (g1) and g6 predominate, no prior studies have been conducted investigating associations of IFNL3/4 polymorphisms with spontaneous clearance (SC) or HCV viral load (VL) in chronic infection. In this study, we have investigated the host genetic variations in IFNL loci to determine the association of IFNL3/4 polymorphisms with HCV SC and baseline VLs in a Vietnamese HCV-seropositive cohort. The majority of the cohort harboured major homozygous polymorphisms in IFNL3/4 cluster (i.e. rs12979860-CC: 82.7%; rs8099917-TT: 84.8% and rs368234815-TT/TT: 85.5%) and the SC rates in these groups were 15.8%, 16.3% and 15.7%, respectively. In the minor allele groups, the resolution rates were lower (12% in rs12979860 non-CC, 9.1% in rs8099917 non-TT and 9.5% in rs368234815 non-TT/TT). Furthermore, in individuals harbouring minor alleles, females achieved higher SC rates than males. HCV g6-infected rs12979860 major homozygous individuals had significantly higher viral loads than individuals with minor alleles (CC: 6.56 log IU/ml vs. non-CC: 5.66 log IU/ml; P = 0.021). The association between IFNL3/4 genotypes with elevated HCV VL observed in HCV g6-infected individuals may have implications for the progression of liver disease in Southeast Asian countries where this viral genotype predominates and therefore warrants further studies.
Literature
1.
2.
go back to reference Hajarizadeh B, Grebely J, Dore GJ (2013) Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 10:553–562CrossRefPubMed Hajarizadeh B, Grebely J, Dore GJ (2013) Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 10:553–562CrossRefPubMed
3.
go back to reference Micallef JM, Kaldor JM, Dore GJ (2006) Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 13:34–41CrossRefPubMed Micallef JM, Kaldor JM, Dore GJ (2006) Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 13:34–41CrossRefPubMed
4.
go back to reference Ge D, Fellay J, Thompson AJ et al (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399–401CrossRefPubMed Ge D, Fellay J, Thompson AJ et al (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399–401CrossRefPubMed
5.
go back to reference Tanaka Y, Nishida N, Sugiyama M et al (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105–1109CrossRefPubMed Tanaka Y, Nishida N, Sugiyama M et al (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105–1109CrossRefPubMed
6.
go back to reference Rauch A, Kutalik Z, Descombes P et al (2010) Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138:1338–1345 (1345.e1331-1337) CrossRefPubMed Rauch A, Kutalik Z, Descombes P et al (2010) Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138:1338–1345 (1345.e1331-1337) CrossRefPubMed
7.
go back to reference Matsuura K, Watanabe T, Tanaka Y (2014) Role of IL28B for chronic hepatitis C treatment toward personalized medicine. J Gastroenterol Hepatol 29:241–249CrossRefPubMed Matsuura K, Watanabe T, Tanaka Y (2014) Role of IL28B for chronic hepatitis C treatment toward personalized medicine. J Gastroenterol Hepatol 29:241–249CrossRefPubMed
8.
go back to reference Nguyen LT, Gray E, Dean J et al (2015) Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype-1-infected individuals. Antivir Ther 20:865–869CrossRefPubMed Nguyen LT, Gray E, Dean J et al (2015) Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype-1-infected individuals. Antivir Ther 20:865–869CrossRefPubMed
10.
go back to reference Shebl FM, Pfeiffer RM, Buckett D et al (2011) IL28B rs12979860 genotype and spontaneous clearance of hepatitis C virus in a multi-ethnic cohort of injection drug users: evidence for a supra-additive association. J Infect Dis 204:1843–1847CrossRefPubMedPubMedCentral Shebl FM, Pfeiffer RM, Buckett D et al (2011) IL28B rs12979860 genotype and spontaneous clearance of hepatitis C virus in a multi-ethnic cohort of injection drug users: evidence for a supra-additive association. J Infect Dis 204:1843–1847CrossRefPubMedPubMedCentral
11.
go back to reference EASL (2014) EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 60:392–420CrossRef EASL (2014) EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 60:392–420CrossRef
12.
go back to reference Prokunina-Olsson L, Muchmore B, Tang W et al (2013) A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 45:164–171CrossRefPubMedPubMedCentral Prokunina-Olsson L, Muchmore B, Tang W et al (2013) A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 45:164–171CrossRefPubMedPubMedCentral
13.
go back to reference Dunford L, Carr MJ, Dean J et al (2012) Hepatitis C virus in Vietnam: high prevalence of infection in dialysis and multi-transfused patients involving diverse and novel virus variants. PLoS One 7:e41266CrossRefPubMedPubMedCentral Dunford L, Carr MJ, Dean J et al (2012) Hepatitis C virus in Vietnam: high prevalence of infection in dialysis and multi-transfused patients involving diverse and novel virus variants. PLoS One 7:e41266CrossRefPubMedPubMedCentral
14.
go back to reference Wasitthankasem R, Vongpunsawad S, Siripon N et al (2015) Genotypic distribution of hepatitis C virus in Thailand and southeast Asia. PLoS One 10:e0126764CrossRefPubMedPubMedCentral Wasitthankasem R, Vongpunsawad S, Siripon N et al (2015) Genotypic distribution of hepatitis C virus in Thailand and southeast Asia. PLoS One 10:e0126764CrossRefPubMedPubMedCentral
15.
go back to reference Daniel HD, Grant PR, Garson JA, Tedder RS, Chandy GM, Abraham P (2008) Quantitation of hepatitis C virus using an in-house real-time reverse transcriptase polymerase chain reaction in plasma samples. Diagn Microbiol Infect Dis 61:415–420CrossRefPubMed Daniel HD, Grant PR, Garson JA, Tedder RS, Chandy GM, Abraham P (2008) Quantitation of hepatitis C virus using an in-house real-time reverse transcriptase polymerase chain reaction in plasma samples. Diagn Microbiol Infect Dis 61:415–420CrossRefPubMed
16.
go back to reference Pybus OG, Barnes E, Taggart R et al (2009) Genetic history of hepatitis C virus in East Asia. J Virol 83:1071–1082CrossRefPubMed Pybus OG, Barnes E, Taggart R et al (2009) Genetic history of hepatitis C virus in East Asia. J Virol 83:1071–1082CrossRefPubMed
17.
go back to reference Kalaghatgi P, Sikorski AM, Knops E et al (2016) Geno2pheno[HCV]—a web-based interpretation system to support hepatitis C treatment decisions in the era of direct-acting antiviral agents. PLoS One 11:e0155869CrossRefPubMedPubMedCentral Kalaghatgi P, Sikorski AM, Knops E et al (2016) Geno2pheno[HCV]—a web-based interpretation system to support hepatitis C treatment decisions in the era of direct-acting antiviral agents. PLoS One 11:e0155869CrossRefPubMedPubMedCentral
18.
go back to reference Collison M, Chin JL, Abu Shanab A et al (2015) Homozygosity for HLA group 2 alleles predicts treatment failure with interferon-alpha and ribavirin in chronic hepatitis C virus genotype 1 infection. J Interferon Cytokine Res 35:126–133CrossRefPubMed Collison M, Chin JL, Abu Shanab A et al (2015) Homozygosity for HLA group 2 alleles predicts treatment failure with interferon-alpha and ribavirin in chronic hepatitis C virus genotype 1 infection. J Interferon Cytokine Res 35:126–133CrossRefPubMed
19.
go back to reference Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H (2014) Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61:S45–S57CrossRefPubMed Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H (2014) Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61:S45–S57CrossRefPubMed
20.
go back to reference Schinazi R, Halfon P, Marcellin P, Asselah T (2014) HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int 34(Suppl 1):69–78CrossRefPubMed Schinazi R, Halfon P, Marcellin P, Asselah T (2014) HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int 34(Suppl 1):69–78CrossRefPubMed
21.
go back to reference Grebely J, Page K, Sacks-Davis R et al (2014) The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 59:109–120CrossRefPubMed Grebely J, Page K, Sacks-Davis R et al (2014) The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 59:109–120CrossRefPubMed
22.
go back to reference Watanabe H, Saito T, Shinzawa H et al (2003) Spontaneous elimination of serum hepatitis C virus (HCV) RNA in chronic HCV carriers: a population-based cohort study. J Med Virol 71:56–61CrossRefPubMed Watanabe H, Saito T, Shinzawa H et al (2003) Spontaneous elimination of serum hepatitis C virus (HCV) RNA in chronic HCV carriers: a population-based cohort study. J Med Virol 71:56–61CrossRefPubMed
23.
go back to reference Scott JD, McMahon BJ, Bruden D et al (2006) High rate of spontaneous negativity for hepatitis C virus RNA after establishment of chronic infection in Alaska Natives. Clin Infect Dis 42:945–952CrossRefPubMed Scott JD, McMahon BJ, Bruden D et al (2006) High rate of spontaneous negativity for hepatitis C virus RNA after establishment of chronic infection in Alaska Natives. Clin Infect Dis 42:945–952CrossRefPubMed
24.
go back to reference Bulteel N, Partha Sarathy P, Forrest E et al (2016) Factors associated with spontaneous clearance of chronic hepatitis C virus infection. J Hepatol 65:266–272CrossRefPubMed Bulteel N, Partha Sarathy P, Forrest E et al (2016) Factors associated with spontaneous clearance of chronic hepatitis C virus infection. J Hepatol 65:266–272CrossRefPubMed
25.
go back to reference Thong VD, Wasitthankasem R, Tangkijvanich P, Vongpunsawad S, Poovorawan Y (2015) Prevalence of thymine-adenine dinucleotide repeat, IL28B and IFNL4 in thai population and correlation with spontaneous clearance and treatment outcome of hepatitis C infection. PLoS One 10:e0125400CrossRefPubMedPubMedCentral Thong VD, Wasitthankasem R, Tangkijvanich P, Vongpunsawad S, Poovorawan Y (2015) Prevalence of thymine-adenine dinucleotide repeat, IL28B and IFNL4 in thai population and correlation with spontaneous clearance and treatment outcome of hepatitis C infection. PLoS One 10:e0125400CrossRefPubMedPubMedCentral
26.
go back to reference Rao HY, Sun DG, Jiang D et al (2012) IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. J Viral Hepat 19:173–181CrossRefPubMed Rao HY, Sun DG, Jiang D et al (2012) IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. J Viral Hepat 19:173–181CrossRefPubMed
27.
go back to reference Lee MH, Yang HI, Lu SN et al (2015) Polymorphisms near the IFNL3 gene associated with HCV RNA spontaneous clearance and hepatocellular carcinoma risk. Sci Rep 5:17030CrossRefPubMedPubMedCentral Lee MH, Yang HI, Lu SN et al (2015) Polymorphisms near the IFNL3 gene associated with HCV RNA spontaneous clearance and hepatocellular carcinoma risk. Sci Rep 5:17030CrossRefPubMedPubMedCentral
28.
go back to reference Ikezaki H, Furusyo N, Hiramine S et al (2016) Association of IL28B rs8099917 genotype and female sex with spontaneous clearance of hepatitis C virus infection: a Japanese cross-sectional study. Arch Virol 161:641–648CrossRefPubMed Ikezaki H, Furusyo N, Hiramine S et al (2016) Association of IL28B rs8099917 genotype and female sex with spontaneous clearance of hepatitis C virus infection: a Japanese cross-sectional study. Arch Virol 161:641–648CrossRefPubMed
29.
go back to reference Heim MH, Bochud PY, George J (2016) Host—hepatitis C viral interactions: the role of genetics. J Hepatol 65:S22–S32CrossRefPubMed Heim MH, Bochud PY, George J (2016) Host—hepatitis C viral interactions: the role of genetics. J Hepatol 65:S22–S32CrossRefPubMed
30.
go back to reference Duggal P, Thio CL, Wojcik GL et al (2013) Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med 158:235–245CrossRefPubMedPubMedCentral Duggal P, Thio CL, Wojcik GL et al (2013) Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med 158:235–245CrossRefPubMedPubMedCentral
31.
go back to reference Xu Y, Huang P, Yue M et al (2016) A novel polymorphism near HLA class II region is associated with spontaneous clearance of HCV and response to interferon treatment in Chinese patients. J Hum Genet 61:301–305CrossRefPubMed Xu Y, Huang P, Yue M et al (2016) A novel polymorphism near HLA class II region is associated with spontaneous clearance of HCV and response to interferon treatment in Chinese patients. J Hum Genet 61:301–305CrossRefPubMed
32.
go back to reference Hajarizadeh B, Grady B, Page K et al (2014) Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) study. J Clin Virol 61:430–434CrossRefPubMedPubMedCentral Hajarizadeh B, Grady B, Page K et al (2014) Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) study. J Clin Virol 61:430–434CrossRefPubMedPubMedCentral
33.
go back to reference Liu L, Fisher BE, Thomas DL, Cox AL, Ray SC (2012) Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology 55:1684–1691CrossRefPubMedPubMedCentral Liu L, Fisher BE, Thomas DL, Cox AL, Ray SC (2012) Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology 55:1684–1691CrossRefPubMedPubMedCentral
34.
go back to reference Grady BP, Prins M, Rebers S, Molenkamp R, Geskus RB, Schinkel J (2015) BMI, male sex and IL28B genotype associated with persistently high hepatitis C virus RNA levels among chronically infected drug users up to 23 years following seroconversion. J Viral Hepat 22:263–271CrossRefPubMed Grady BP, Prins M, Rebers S, Molenkamp R, Geskus RB, Schinkel J (2015) BMI, male sex and IL28B genotype associated with persistently high hepatitis C virus RNA levels among chronically infected drug users up to 23 years following seroconversion. J Viral Hepat 22:263–271CrossRefPubMed
35.
go back to reference Bucci C, von Delft A, Christian A et al (2013) ‘Favourable’ IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy. J Gen Virol 94:1259–1265CrossRefPubMed Bucci C, von Delft A, Christian A et al (2013) ‘Favourable’ IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy. J Gen Virol 94:1259–1265CrossRefPubMed
36.
go back to reference Hajarizadeh B, Grady B, Page K et al (2015) Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study. J Viral Hepat 22:708–717CrossRefPubMedPubMedCentral Hajarizadeh B, Grady B, Page K et al (2015) Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study. J Viral Hepat 22:708–717CrossRefPubMedPubMedCentral
37.
go back to reference Uccellini L, Tseng FC, Monaco A et al (2012) HCV RNA levels in a multiethnic cohort of injection drug users: human genetic, viral and demographic associations. Hepatology 56:86–94CrossRefPubMedPubMedCentral Uccellini L, Tseng FC, Monaco A et al (2012) HCV RNA levels in a multiethnic cohort of injection drug users: human genetic, viral and demographic associations. Hepatology 56:86–94CrossRefPubMedPubMedCentral
38.
go back to reference Abdelwahab SF, Zakaria Z, Allam WR et al (2015) Interleukin 28B.rs12979860 genotype does not affect hepatitis C viral load in Egyptians with genotype 4 chronic infection. Arch Virol 160:2833–2837CrossRefPubMed Abdelwahab SF, Zakaria Z, Allam WR et al (2015) Interleukin 28B.rs12979860 genotype does not affect hepatitis C viral load in Egyptians with genotype 4 chronic infection. Arch Virol 160:2833–2837CrossRefPubMed
39.
go back to reference Messina J, Humphreys I, Flaxman A et al (2015) Global distribution and prevalence of hepatitis C virus genotypes. Hapatology 61:77–87CrossRef Messina J, Humphreys I, Flaxman A et al (2015) Global distribution and prevalence of hepatitis C virus genotypes. Hapatology 61:77–87CrossRef
40.
go back to reference Noureddin M, Wright EC, Alter HJ et al (2013) Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology 58:1548–1557CrossRefPubMedPubMedCentral Noureddin M, Wright EC, Alter HJ et al (2013) Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology 58:1548–1557CrossRefPubMedPubMedCentral
41.
go back to reference Grebely J, Grady B, Hajarizadeh B, Page K, Dore GJ, Group INCS (2014) Disease progression during advanced fibrosis: IL28B genotype or HCV RNA levels? Hepatology 59:1650–1651CrossRefPubMedPubMedCentral Grebely J, Grady B, Hajarizadeh B, Page K, Dore GJ, Group INCS (2014) Disease progression during advanced fibrosis: IL28B genotype or HCV RNA levels? Hepatology 59:1650–1651CrossRefPubMedPubMedCentral
42.
go back to reference Ishiguro S, Inoue M, Tanaka Y, Mizokami M, Iwasaki M, Tsugane S (2011) Impact of viral load of hepatitis C on the incidence of hepatocellular carcinoma: a population-based cohort study (JPHC Study). Cancer Lett 300:173–179CrossRefPubMed Ishiguro S, Inoue M, Tanaka Y, Mizokami M, Iwasaki M, Tsugane S (2011) Impact of viral load of hepatitis C on the incidence of hepatocellular carcinoma: a population-based cohort study (JPHC Study). Cancer Lett 300:173–179CrossRefPubMed
43.
Metadata
Title
Association of interferon lambda polymorphisms with elevated baseline viral loads in chronic hepatitis C virus genotype 6 infection
Authors
Linh Thuy Nguyen
Dzung Van Nguyen
Michael J. Carr
William W. Hall
Lan Anh Nguyen
Publication date
01-01-2018
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 1/2018
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-017-3583-y

Other articles of this Issue 1/2018

Archives of Virology 1/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine